Press Releases Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
70.57 ^USD	+0.28%		-2.62%	-1.19%

Apr. 08	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
Apr. 03	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024	Apr. 23	BU
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K	Apr. 19	PU
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	BU
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI	Apr. 04	AQ
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™	Apr. 03	BU
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference	Mar. 05	BU
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	Mar. 05	AQ
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 04	BU
Ligand: Q4 Earnings Snapshot	Feb. 27	AQ
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 27	BU
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	Feb. 22	BU
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	Feb. 19	AQ
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	Feb. 16	BU
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	Feb. 13	BU
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 01	BU
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene	Jan. 12	AQ
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum	Jan. 05	BU
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance	Dec. 12	BU
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City	Dec. 06	BU
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications	Dec. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Press Releases

Filters